None
Quote | Camurus AB (OTCMKTS:CAMRF)
Last: | $46.15 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $46.15 |
High: | $0 |
Low: | $0 |
Volume: | 20 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Camurus AB (OTCMKTS:CAMRF)
2023-12-20 00:16:06 ET Summary With the significant treatment gap, Indivior is well positioned for growth as more patients receive treatment for Opioid Use Disorder. Sublocade, the first FDA-approved buprenorphine LAI for OUD, has seen impressive growth but faces competition from ...
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire LUND, Sweden , May 3, 2021 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announced that the Australian regulatory agency, the Therapeutic Good...
Message Board Posts | Camurus AB (OTCMKTS:CAMRF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Camurus AB Company Name:
CAMRF Stock Symbol:
OTCMKTS Market:
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire LUND, Sweden , May 3, 2021 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announced that the Australian regulatory agency, the Therapeutic Good...
Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire LUND, Sweden , March 26, 2021 /PRNewswire/ -- Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Eu...
Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation Both weekly and daily formulations of setmelanotide were observed to be safe and well-tolerated LUND, Sweden , June 24, 2020 /PRNewswire/ -- Camurus' partner Rhyt...